invoX

UK-based biotechnology company invoX, an international subsidiary established by China-based Sino Biopharmaceutical Group in 2021, is reportedly undergoing a strategic downsizing. The company is focusing its efforts on its lead candidate, the CD137/PD-L1 bispecific molecule FS222, while reducing its workforce. According to Endpoints News, which cited a direct email from…